Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (2290)	4/13/1999 8:37:00 PM
From: BMcV	Read Replies (1) \| Respond to of 10280

Volume was actually low until we hit the 112 area. I don't think any institutions were selling. Here's my nutty guess on today's action. Tax payments are due day after tomorrow. If you have a tax bill to pay, why compound the unpleasant by selling your losers? Much better to sell a winner, take a nice profit, write that check and smile all the way to the post office. Hey, last week they were talking about last-minute IRA contributions driving the market up, which is pretty far-fetched since hardly anyone makes last-minute contributions and the limit is only $2k. Bob, what LEAPS are you looking at? I might finally take the plunge.

To: quidditch who wrote (2290)	4/13/1999 11:56:00 PM
From: BDR	Read Replies (1) \| Respond to of 10280

<< Thread, correct me if I'm wrong: does any of SEPR's pipeline of licensed and co-promoted or self-developed drugs deal with urinary incontinence (ICE for oxybutynin)--I didn't think so...>> From the Sepracor web site (http://www.sepracor.com/html/3.science/therap.html) Sepracor's Urology Drugs: (S)-oxybutynin - a potential treatment for urinary incontinence with potentially reduced anticholinergic side effects including dry mouth, restlessness, nausea and heart palpitations. (S)-oxybutynin will progress to Phase IIb trials in early 1999. (S)-doxazosin - a potential BPH treatment with potentially decreased orthostatic hypotension compared to Cardura®.